The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model
- PMID: 22653982
- PMCID: PMC3365141
- DOI: 10.1136/bmj.e3657
The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model
Abstract
Objective: To model the long term effectiveness and cost effectiveness of daily dark chocolate consumption in a population with metabolic syndrome at high risk of cardiovascular disease.
Design: Best case scenario analysis using a Markov model.
Setting: Australian Diabetes, Obesity and Lifestyle study.
Participants: 2013 people with hypertension who met the criteria for metabolic syndrome, with no history of cardiovascular disease and not receiving antihypertensive therapy.
Main outcome measures: Treatment effects associated with dark chocolate consumption derived from published meta-analyses were used to determine the absolute number of cardiovascular events with and without treatment. Costs associated with cardiovascular events and treatments were applied to determine the potential amount of funding required for dark chocolate therapy to be considered cost effective.
Results: Daily consumption of dark chocolate (polyphenol content equivalent to 100 g of dark chocolate) can reduce cardiovascular events by 85 (95% confidence interval 60 to 105) per 10,000 population treated over 10 years. $A40 (£25; €31; $42) could be cost effectively spent per person per year on prevention strategies using dark chocolate. These results assume 100% compliance and represent a best case scenario.
Conclusions: The blood pressure and cholesterol lowering effects of dark chocolate consumption are beneficial in the prevention of cardiovascular events in a population with metabolic syndrome. Daily dark chocolate consumption could be an effective cardiovascular preventive strategy in this population.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at
Figures
References
-
- World Health Organization. Cardiovascular diseases: fact sheet No 317. WHO, 2007.
-
- Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066-72. - PubMed
-
- Lippi G, Franchini M, Montagnana M, Favaloro EJ, Guidi GC, Targher G. Dark chocolate: consumption for pleasure or therapy? J Throm Thrombolysis 2009;28:482-8. - PubMed
-
- Egan BM, Laken MA, Donovan JL, Woolson RF. Does dark chocolate have a role in the prevention and management of hypertension? Commentary on the evidence. Hypertension 2010;55:1289-95. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous